SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Merck Gets Positive EU CHMP Opinion for WELIREG Plus Lenvatinib

The CHMP backed WELIREG (belzutifan) with lenvatinib for adults with advanced clear-cell renal cell carcinoma after prior treatment.

MRK

Related stories